PMLiVE’s Top Pharma list has been launched, ranking the top companies in the pharmaceutical industry by their global sales, as well as by their revenues in the US, Europe and Japan.
The list also features profile pages for each company and additional rankings for biologic, cardiovascular, central nervous system, immunology, metabolic, ophthalmology, respiratory and oncology sales.
The ranking of the top pharma companies has been compiled from GlobalData’s pharmaceutical revenue figures, which are based on sales of prescription medicines, including generics drugs. The rankings include historical data from 2006 to 2023 and forecast data for 2024 to 2030.
Johnson & Johnson has claimed the top spot on the list of Top 25 Pharma Companies based on Global sales. The company boasted $54,103m in global revenue in 2023, with this predicted to grow to $58,941m in 2025 and to $80,170m in 2030.
AbbVie and Merck & Co have taken second and third place in Global sales, respectively, with Roche, Pfizer, Novartis, Bristol Myers Squibb, AstraZeneca, Sanofi and GSK also making the top ten.
Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and forecasted to achieve $46,513m in 2025 and $56,394m in 2030. Bristol Myers Squibb and Johnson & Johnson have taken second and third place, respectively, with Roche following close behind in fourth place and Merck & Co in fifth.
Pfizer has come out on top on the list of Top 25 Pharma Companies Europe Rx, with $9,587m in Europe Rx revenue in 2023, and expected to achieve $812m in 2025 and $1,145m in 2030. Sanofi and Roche follow in second and third place, respectively, and are joined in the top ten by AstraZeneca, GSK, Novo Nordisk, Takeda, Teva, Gilead Sciences and Daiichi Sankyo.
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies – including over 70% of FTSE 100 and 60% of Fortune 100 firms – to make timely, informed decisions through unique data, expert analysis and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/